Teva Reaches $420M Deal To End Investors' Price-Fixing Suit
Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to resolve an investor class action accusing the pharmaceutical giant of being at the center of an industrywide price-fixing scheme....To view the full article, register now.
Already a subscriber? Click here to view full article